Alnylam Pharmaceuticals, Inc. (ALNY)
401.50
+4.25
(+1.07%)
USD |
NASDAQ |
Dec 31, 14:23
Alnylam Pharmaceuticals Research and Development Expense (Quarterly): 358.81M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen, Inc. | 369.60M |
| Insmed, Inc. | 186.42M |
| Pfizer Inc. | 2.492B |
| Glaukos Corp. | 38.07M |
| BridgeBio Pharma, Inc. | 112.87M |